ProMis Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto
Ontario
M4S 3E2
United States
Website: http://promisneurosciences.com/
109 articles with ProMis Neurosciences, Inc.
-
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
10/8/2019
Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
9/16/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that Executive Chairman, Eugene Williams will participate on an executive panel at the Fall Investor Summit being held today at noon at the JW Marriot Essex House
-
ProMIS Neurosciences to Present at HC Wainwright Investment Conference
9/3/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC.
-
ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
8/27/2019
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board.
-
ProMIS Neurosciences Announces Second Quarter 2019 Results
8/13/2019
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
-
ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
7/18/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer's disease, at the annual Alzheimer's Association International Conference® (AAIC) in Los Angeles.
-
ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
7/10/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer's disease,
-
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
7/9/2019
Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease
-
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
6/27/2019
Data presented at Keystone Symposium on Neurodegenerative Diseases
-
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
6/19/2019
Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer
-
ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
6/5/2019
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers
-
ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
5/29/2019
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases" on May 30, 2019.
-
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
5/28/2019
Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease
-
ProMIS Neurosciences Announces First Quarter 2019 Results
5/14/2019
Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer's and Parkinson's diseases and ALS
-
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
4/23/2019
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
-
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
3/26/2019
Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS
-
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
-
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
3/21/2019
Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
-
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD 2019 Conference
3/19/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease